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Infectious diseases are a major global health burden accounting for approximately 15
million deaths annually, many from drug resistant pathogenic agents, with a significant
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tuberculosis (TB) has been accompanied by the rapid spread of multi-drug resistance TB
(MDR-TB) resulting from Mycobacterium tuberculosis (Mtb) strains that fail to respond to
the first-line drugs, rifampin and isoniazid. Currently, <5% of ~0.5 million MDR-TB cases
estimated globally are appropriately diagnosed and treated due in part to the long assay
turnaround time associated with conventional culture-based drug susceptibility testing.[8]
Quantitative PCR (qPCR), line probe assays, or home-brewed nucleic acid amplification
tests (NAATs), have recently been used to identify MDR-TB. These tests provide shorter
assay turnaround times compared to culture, but depend on sophisticated laboratory
infrastructure and well-trained personnel to ensure accurate, reliable, and reproducible
results. The WHO expert group recently recommended two NAAT line probe assays,
INNO-LiPA Rif.TB from Innogenetics and MTBDRplus from Hain Lifescience, both of
which employ multiplexed PCR reverse hybridization approaches. Line probe assays,
however, are not designed to interrogate a mixed population of drug resistant and
susceptible bacterial populations,[9–11] because sequence-specific array hybridization is
unable to detect low abundance single base variations due to cross hybridization artifacts,
especially in high GC content regions.
Several groups have developed partial or fully integrated microfluidic devices for carrying
out NAATs for infectious diseases.[12–17] For example, Cepheid's GeneXpert MDR-TB
system performs qPCR using Taqman probes for Mtb and 5 rifampin resistance mutations,
providing results in nearly 2 h.[18] However, many of these devices are made from silicon/
glass materials and thus require direct photolithographic processing to manufacture the
desired structures, which increases the production cost of devices.
Herein, we describe a modular design approach for an assay and hardware to detect/identify
MDR-TB. The molecular assay was designed to interrogate single base variations in codons
516, 526, and 531 (using the numbering system of E. coli rpoB) in the rifampin-resistance
determining region (RRDR) of the rpoB gene, which was used as surrogate markers for
MDR-TB.[19, 20] The multi-step assay was carried out within a modular thermoplastic fluidic
cartridge operated by the accompanying support peripherals packaged into a small
instrument (1' × 1' × 1'). No operator intervention was required once the clinical sample
(sputum) was loaded into the fluidic cartridge. This system offered advantages compared to
existing NAAT systems. For example, to accommodate low-resource setting scenarios
where operator expertise is limited, the hardware provided full process automation. The
fluidic system consisted of a cartridge made from thermoplastics with the desired structures
fabricated in a high-production format using molding to keep chip cost low for one-time use
applications (in vitro diagnostics) appropriate for resource limited settings.
Additional design concepts employed in the fluidic cartridge included: (1) A hybrid modular
architecture, which combined several task-specific modules interconnected to a fluidic
motherboard with the material selected to optimize performance. (2) Most of the active
elements were poised off-chip to keep chip cost low. (3) The embossing step was used to not
only create the fluidic network, but other necessary device components as well, such as the
DNA extraction bed, thermal isolation grooves, valve seats and waveguides. The fluidic
cartridge could easily be reconfigured without requiring re-engineering to accommodate
alternative assays. For example, a universal array module could be replaced with a
colorimetric readout module to simplify the readout hardware. Compared to
monolithic[12–16] or LEGO approaches,[21, 22] the hybrid modular architecture balanced the
efficiency and flexibility in fluidic cartridge design and material selection.
Collectively, more than 95% of resistance to rifampin is associated with missense, insertion,
and deletion mutations in the RRDR of the rpoB gene. Single base variations in codons 516,
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526 or 531 are most frequently found in rifampin-resistant Mtb strains world-wide. We
therefore developed a PCR/LDR/universal array assay to detect sequence variations
harbored within these codons (see Figure 1).[23]
The PCR/LDR/universal array approach employed a high fidelity Taq ligase and decoupled
the mutation discrimination step from the amplification and hybridization steps.[23–27] The
assay demostrated the following important attributes: (1) The closely clustered drug
resistance mutations of MDR-TB could be interrogated using a uniplex PCR. Therefore,
careful design of primers with similar Tm's and problems with uneven amplification
produced by different targets was negated. (2) Only the specific drug resistant sequence
variations generate positive results. Silent mutations, which do not confer drug resistance,
did not generate false positive results. (3) Hetero-resistant Mtb containing a low abundance
of drug resistant strains (~1%) in patients with emerging drug resistance could be identified
due to the high discriminatory capability of the ligase enzyme. (4) Two amplification steps
were used, an exponential amplification associated with the PCR and a linear amplification
resulting from the LDR, which improved the limit-of-detection of the assay.
The fluidic cartridge shown in Figures 2, S1 and S2 (Supporting Information) was designed
to include five different processing steps; cell lysis, solid phase DNA extraction (SPE),
PCR, LDR and universal array hybridization. The thermal steps (cell lysis, PCR and LDR)
were situated on a fluidic motherboard while the SPE and universal array were placed on
two different modules interconnected to the motherboard. A detailed description of how
each module and the motherboard were fabricated is included in the Supporting Information.
The modules and motherboard were hot embossed from a particular thermoplastic, selected
to optimize performance of each specific processing step. To minimize post-assembly steps,
embossing was used not only to generate fluidic networks, but also specific components
required for proper operation of the module or motherboard. For example, the SPE module
required the use of polycarbonate, which was suitable for the selective capture of nucleic
acids to its surface following photoactivation.[28] Further, to increase the available surface
area required to increase the DNA load, high aspect ratio micropillars were manufactured
into the SPE bed during embossing of the fluidic network, thus obviating the need for
packing the SPE bed with externally added beads (see Supporting Information, Figure S1).
Polycarbonate has a relatively high glass transition temperature, which makes it a suitable
material for thermal reactions and thus, the ideal material for the fluidic motherboard, which
performed thermal reactions requiring 65°C to 95°C operation. Polycarbonate also has a
relatively large elongation at break threshold such that it can be used as a microfluidic valve
membrane. Using polycarbonate as the cover plate for the motherboard obviated the need
for an additional post-molding assembly step as the valve membranes were attached to the
fluidic network in the same lamination step used to enclose the fluidic network with the
cover plate. However, polycarbonate is not compatible with ultra-sensitive fluorescence
detection because of its relatively high background.
Poly(methyl methacrylate), PMMA, demonstrates good optical clarity and minimal non-
specific adsorption artifacts, making it an ideal material for construction of the universal
array module.[29] The universal array was poised within a microchannel resident on this
module to reduce the time for probe addressing by minimizing diffusional constraints.[30–32]
Waveguides were fabricated using double-sided embossing with simple plasma activation of
the PMMA surface to allow for covalent attachment of the zipcode probes to the waveguide
(Supporting Information, Figure S3).[33] Finally, printing of the zipcode probes could be
performed using conventional DNA spotting equipment prior to enclosure of the fluidic
network because of the low temperature required for bonding the cover plate to the substrate
containing the probes.[34]
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Figures 2B and S1B provide schematic drawings and SEM images of the SPE module.
Design specifics on the SPE module can be found in the Supporting Information. Figure 2C
shows a schematic of the operation of the polycarbonate membrane valves with solenoid
actuation. These micro-valves could withstand head pressures up to 105 psi without leakage,
which is more than an order of magnitude higher pressure load than PDMS valves.[35]
The thermal reactors situated on the fluidic motherboard (Figures 2A, S1A, and S1C)
incorporated a continuous flow format, which provided ultrafast PCR amplification because
extension times are limited by the kinetics of the polymerase for properly designed thermal
reactors.[36] Several thermal management structures were also included to further improve
amplification efficiency (Figure S4), such as backside thermal isolation grooves, a thin
substrate and copper plates to give a uniform temperature distribution throughout a
particular thermal zone.[37] Further, a dual-depth channel (200 μm and 100 μm) was
employed to provide sufficient residence time within the polymerase extension zone to
generate full length PCR products during each cycle while operating at a fixed linear flow
velocity (Figures 2D and S1C). For a detailed discussion on the operation of the fluidic
cartridge, see the Supporting Information.
We performed a series of assays using different positive and negative controls that were
processed using the modular fluidic cartridge. The results concurred with those expected, as
shown in Figure S5. For example, supplying an input of E. coli cells did not result in postive
fluorescence signals on the universal array. However, input of a wild-type Mtb strain
generated fluorescence signatures at the appropriate spots of the array (Figure S5).
We were interested in evaluating the minimum number of Mtb cells required to provide
positive results using our system and whether results could meet the needed level for clinical
diagnosis. To determine the limit-of-detection, assays were conducted using a serial dilution
of cultured H37Rv cells as the input. As few as 50 Mtb cells could be successfully detected,
representing a 100-fold improvement in sensitivity compared to current clinical smear tests,
which require 5,000–10,000 bacilli in 1 mL of sputum.
Hetero-resistant Mtb is defined as the coexistence of mixed populations of drug susceptible
and resistant Mtb strains in the same patient, which is considered as a preliminary stage to
full resistance. These cases result either from super-infection or from selection pressure
during antibiotic treatment. The occurrence of hetero-resistance can be as high as
20%.[10, 11] To evaluate the ability of our system to identify a minority population of drug
resistant Mtb strains, a series of control hetero-resistance samples containing increasing
percentages of a rifampin resistant strain (S531L) – 0%, 1%, 2%, 5%, 10%, 100% – in a
drug susceptible strain of H37Rv were prepared and analyzed (Figure 3). The fluorescence
intensity from the 531 mutant spot increased with an increased percentage of the rifampin
resistant strain present in the sample while the spot intensity from the 531Wt decreased
(Figure 3C). The fluorescence from the 531 mutant spots run with samples containing as
little as 1% of rifampin resistant strain was calculated to be ~10-fold higher than
fluorescence from those run with samples containing 0% rifampin resistant strains (Figure
3C). Therefore, less than 1% of the drug resistant strain could still be discriminated based on
a 3-fold standard-deviation higher signal than non-specific signal. Very slight levels of
fluorescence were detected from the 531Wt spots run with 100% of the drug resistant strain,
which could be attributed to mis-ligation and/or nonspecific hybridization.[38]
The modular system was challenged with four clinical samples containing either rifampin-
resistant or susceptible Mtb strains. Figure 4 represents results that were consistent with the
phenotype and the genotype of those clinical samples. The analysis of samples YE69
(A516V), 3976-83 (A516V), YE68 (H526Y), 3908-83 (S531L) and 94-2219 (Wt), Figure
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4B–G, identified the correct mutation for each drug-resistant strain as determined by
sequence analysis of the rpoB gene of these clinical isolates.
A colorimetric zipcode array module was developed as detailed in the Supporting
Information in order to simplify the readout by eliminating the need for laser-induced
fluorescence (Figure S6). PMMA wafers containing immobilized zipcode probes were
prepared using a PDMS stencil (Figure S6B). Also, 1.4 nm nanogold-labeled common
primers were used instead of fluorescent dye-labeled primers as shown in Figure S6A. After
LDR and hybridization, the nanogold labels acted as a catalytic site for silver deposition,
which was visible to the naked eye and could be recorded by a digital camera. A drug
susceptible Mtb stain (H37Rv) and a rifampin-resistant strain (S531L) were tested and the
results are shown in Figure S6C. Using this colorimetric test for detection, the Mtb cell
limit-of-detection was found to be 50 cells, similar to that observed using laser-induced
fluorescence detection.
We have reported the development of a modular design approach for both the software
(molecular assay) and hardware (fluidic cartridge and support peripherals) to determine
sequence variations in reporter sequences to detect and identify MDR-TB directly from
sputum samples. The system provided full process automation minimizing operator
expertise requirements and also, generated results in <30 min, which will be a key operating
metric by providing rapid results to allow proper treatment of patients, potentially
minimizing the generation of additional drug resistant strains due to implementation of a full
treatment regimen.
Recently, extremely drug resistant TB (XDR-TB) has been reported. XDR-TB strains
contain mutations responsible for MDR-TB as well as sequence variations resulting in
resistance to second-line drugs. By incorporating a multiplexed PCR and additional LDR
primers, the system presented here can easily be configured to detect sequence variations
responsible for XDR-TB without hardware redesign. The system, both software and
hardware, holds the potential to be a universal platform for identifying genetic sequence
signatures in a variety of applications, including cancer diagnostics,[23, 26, 27] forensic
testing and biothreat pathogen detection and identification in both developing and developed
countries[24] due to the modular design.
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Schematic representation of the molecular assay. Following a primary PCR to generate a
193 bp rpoB amplicon spanning the RRDR, 3 sets of ligase detection reaction (LDR)
primers were used for interrogating missense mutations in codons 516, 526 and 531 of the
rpoB gene. The discriminating primer contained a base complementary to either the wild-
type or mutation sequence at its 3'-end. The common primer was phosphorylated at its 5'-
end and contained a fluorescent dye, Cy5, at its 3'-end. A thermally stable ligase covalently
links the two primers hybridized to the target if there was a perfect match at the locus being
interrogated. The discriminating primer also carried a unique complementary “zipcode”
sequence (cZip) at its 5'-end to direct the LDR product to a specific location on the
“zipcode” universal array.
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Integrated, modular fluidic cartridge for TB analysis. (A) 3D rendering of the cartridge and
the array. 1–7 - fluidic inlets and outlets: 1 - sample inlet, 2 – PCR cocktail inlet, 3 – LDR
cocktail inlet, 4 – ethanol and air inlet, 5 – array wash inlet, 6 – vacuum connection, 7 –
waste. V1–V6 – on-chip membrane valves (note that V2 is positioned next to SPE module on
the cell lysis microchannel and is not visible in the current view). (B) Close-up of the SPE
bed showing DNA capture bed filled with an array of high-aspect ratio pillars. (C)
Schematic operation of the on-chip membrane valve with mechanical actuation – electrically
actuated solenoid presses on the polymer membrane closing the passage of fluid from the
bottom layer through the valve and back to the bottom layer. (D) Geometry of the
continuous flow PCR reactor with dual-depth microchannels for extended residence time in
the extension-zone; Den – denaturation, Ext – extension, PA – primer annealing. (E)
Schematic representation of the detection mode. Laser excitation is coupled to a waveguide
through an integrated prism. Light travelling through the waveguide excites the labeled LDR
products hybridized to the zip code array spotted on the waveguide surface.
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Identification of a mixed-population of drug susceptible (H37Rv) and drug resistant (S531L)
Mtb strains. (A) Layout of the universal array. Spots labeled C were printed with 5'-Cy5
oligonucleotides, and used as quality controls (C) of the printing process. Spots labeled as
Hyb were hybridization controls. Spots labeled as Pos were positive controls (spiked
plasmids). Spots labeled Mtb were Mtb-specific probes targeting an IS6110 insertion
fragment. (B–G) Universal array images for different amounts of the drug resistant and drug
susceptible strains. The percentage of the sample containing the drug resistant strain was 0%
(B), 1% (C), 2% (D), 5% (E), 10% (F) and 100% (G).
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Universal array hybridization results from clinical samples (sputum). (A) Layout of the
universal array with the same designations as that given in Figure 3A. (B) Mtb clinical
isolate (YE69) harbors a mutation in codon 516 of rpoB. (C) Mtb(+) sputum sediment
(3976-83) harbors a mutation in codon 516 of rpoB. (D) Mtb clinical isolate (YE68)
possesses a mutation in codon 526 of rpoB. (E) Mtb(+) sputum sediment (3908-83) harbors
a mutation in codon 531 of rpoB. (F) Mtb-(+) sputum sediment (94-2219) contained no
mutations in rpoB RRDR (Wt). (G) Mtb(−) sputum sediment. The sample identifier is given
in parentheses.
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